Science Direct, doi.org/10.1016/j.mex.2021.101432
Richard Schasfoort, Jos van Weperen, Margot van Amsterdam, Judicaël Parisot, Jan Hendriks, Michelle Koerselman, Marcel Karperien, Anouk Mentink, Martin Bennink, Hans Krabbe, Leon Terstappen, Leontine Mulder
Surface Plasmon Resonance imaging (SPRi) was used to determine the presence and strength of binding of IgG, IgM and IgA against the Receptor Binding Domain (RBD) of SARS-CoV-2 in sera of 119 COVID-19 patients. The SPRi assay measures the antibody isotype levels and the strength of binding to the RBD of ultimate 384 patient samples in one run. It turns out that during the course of the disease, the IgG levels and strength of binding increased while generally the IgM and IgA levels go down. Recovered patients all show high strength of binding of the IgG type to the RBD protein. The anti-RBD immunoglobulins SPRi assay provides additional insights in the immune status of patients recovering from COVID-19 and this new method can furthermore be applied for the assessment of the quality of the immune reaction of healthy individuals to SARS-CoV-2 in vaccination programs.
To download the rest of the peer-reviewed publication, please fill out the short form below. Thank you.